Cencora, Inc. (NYSE: COR), formerly known as AmerisourceBergen, is one of the world’s largest pharmaceutical distribution companies with annual revenue exceeding $321 billion and operations spanning more than 50 countries. Robert P. Mauch became President and CEO of Cencora on October 1, 2024, succeeding Steven H. Collis, who transitioned to the role of Executive Chairman. A pharmacist and entrepreneur by background, Mauch holds both a Pharm.D. and a Ph.D. and founded Xcenda, a health economics consulting firm that was acquired by what was then AmerisourceBergen in 2007. With over 30 years of experience in pharmaceutical care, Mauch now leads Cencora’s 46,000-strong global workforce and a business that distributes drugs to pharmacies, hospitals, and healthcare providers worldwide.
(Suggested: Pfizer CEO Email & Net Worth – Albert Bourla Salary)
Robert P. Mauch – Quick Facts
Cencora Competitors
Cencora operates in the highly concentrated pharmaceutical distribution industry, where the “Big Three” wholesalers control over 90% of the U.S. drug distribution market. Key competitors of Cencora include:
- McKesson Corporation – Largest U.S. pharmaceutical distributor (~41% market share)
- Cardinal Health – Third-largest U.S. drug wholesaler (~24% market share)
- Henry Schein – Specialty healthcare distribution
- Owens & Minor – Medical products distribution
- Morris & Dickson – Regional pharmaceutical distributor
- FFF Enterprises – Specialty pharmaceutical distribution
- Alliance Healthcare (Walgreens Boots Alliance) – International pharmaceutical distribution
Robert P. Mauch Net Worth 2026 – Cencora CEO Salary
As of 2026, Robert P. Mauch’s net worth is estimated at approximately $40–45 million USD, based on his disclosed Cencora stock holdings and SEC filings. According to insider trading records, Mauch beneficially owns approximately 97,968 shares of Cencora stock, which at the current stock price of approximately $360–$372 per share represents holdings worth roughly $35–36 million. Combined with unvested RSUs worth approximately $2.6 million, unearned performance shares with a maximum value of $9.5 million, and vested stock options, his total equity-based wealth in the company is substantial.
Cencora CEO Compensation Breakdown (FY2024)
Cencora Net Worth 2026 – Is Cencora Profitable?
Yes, Cencora is a highly profitable company and one of the largest corporations in the world by revenue. Under Cencora CEO Robert P. Mauch, the company continues the strong financial trajectory established over the past decade.
Cencora Financial Summary (FY2025)
(Recommended: McKesson CEO Email & Net Worth – Brian Tyler Salary)
Cencora CEO Email Address | Robert Mauch Contact
Below are the official contact details for Cencora CEO Robert P. Mauch:
Career & Education – Company, University, & College
Robert P. Mauch’s career spans over three decades in pharmaceutical care, health economics, and healthcare distribution. Below is his complete career timeline:
Robert P. Mauch Career Timeline
Robert P. Mauch began his career as the founder of Xcenda (originally known as Applied Health Outcomes), a health economics, outcomes research, and reimbursement consulting firm serving pharmaceutical companies. When AmerisourceBergen acquired Xcenda in 2007, Mauch joined the company and steadily rose through the leadership ranks.
Over 17 years at the company, Mauch progressed from Senior Vice President to Group President of Pharmaceutical Distribution and Strategic Global Sourcing, then to Executive Vice President and Chief Operating Officer. In each role, he expanded the company’s capabilities in specialty pharmaceuticals, global sourcing, and healthcare solutions. On October 1, 2024, he was named President and CEO, becoming only the second CEO since AmerisourceBergen’s formation.
Education
Robert P. Mauch Wiki – Age, Family, & More
Cencora CEO Robert P. Mauch (age 58) is based in the greater Philadelphia area near the company’s headquarters in Conshohocken, Pennsylvania. He keeps his personal and family life private, and details about his spouse and children are not widely available in public records.
Mauch holds two doctoral degrees — a Pharm.D. and a Ph.D. — making him one of the most academically qualified CEOs in the healthcare industry. His unique combination of clinical pharmacy training and health economics expertise gave him a deep understanding of the pharmaceutical supply chain from both the clinical and business perspectives.
Professional Associations & Board Memberships
- Covenant House of Pennsylvania – Member, Board of Directors
- Healthcare Distribution Alliance (HDA) – Immediate Past Chair
- International Society of Pharmacoeconomics and Outcomes Research (ISPOR) – Member
- American Society of Managed Care Pharmacy (AMCP) – Member
- American Pharmacists Association (APhA) – Member
Fun Fact
Robert Mauch joined Cencora through one of the most unusual CEO origin stories in corporate America: the company acquired his company. He founded Xcenda, a health economics consulting firm, and when AmerisourceBergen purchased Xcenda in 2007, Mauch came along with the deal. Seventeen years later, he rose to lead the entire $321 billion enterprise — proof that sometimes the best path to the C-suite starts by building something worth acquiring.
About Cencora
Cencora, Inc. (formerly AmerisourceBergen) is a global pharmaceutical sourcing and distribution services company headquartered in Conshohocken, Pennsylvania. The company rebranded from AmerisourceBergen to Cencora in August 2023 to better reflect its evolution beyond its merger origins and its growing global presence.
Cencora trades on the New York Stock Exchange under the ticker symbol COR. The company serves as a critical intermediary in the pharmaceutical supply chain, connecting drug manufacturers with pharmacies, hospitals, and healthcare providers. With 46,000 team members across more than 50 countries, Cencora helps ensure that patients around the world have access to the medications they need.
Frequently Asked Questions (FAQ)
Who is the current CEO of Cencora?
The current CEO of Cencora is Robert P. Mauch, who was appointed President and Chief Executive Officer on October 1, 2024. He succeeded Steven H. Collis, who transitioned to the role of Executive Chairman. Cencora was formerly known as AmerisourceBergen.
What is Robert Mauch’s net worth in 2026?
As of 2026, Robert P. Mauch’s net worth is estimated at approximately $40–45 million USD, primarily based on his disclosed Cencora stock holdings of approximately 97,968 shares and equity awards including unvested RSUs and performance shares.
What is Cencora CEO’s salary?
Robert Mauch’s total compensation for fiscal year 2024 was approximately $9.25 million, including a base salary of approximately $1.04 million (increased to $1.35 million upon his CEO promotion), a $2.08 million cash bonus, and $6.0 million in stock awards. His compensation is expected to increase in future disclosures reflecting his full year as CEO.
What is Cencora CEO’s email address?
Cencora CEO Robert P. Mauch’s email address is [email protected]. He can also be reached at Cencora’s corporate headquarters: 1 West First Avenue, Conshohocken, PA 19428, or by phone at (610) 727-7000.
What did Robert Mauch do before becoming CEO?
Before becoming CEO, Robert Mauch served as Executive Vice President and Chief Operating Officer of Cencora from October 2022 to September 2024. He originally founded Xcenda, a health economics consulting firm, and joined the company in 2007 when AmerisourceBergen acquired Xcenda. He holds a Pharm.D. from Mercer University and a Ph.D. from the University of South Carolina.
Why did AmerisourceBergen change its name to Cencora?
AmerisourceBergen rebranded to Cencora in August 2023 to reflect its evolution beyond its merger origins (the original name combined AmeriSource and Bergen Brunswig). The new name better represents the company’s focus on global healthcare solutions and its operations across more than 50 countries.
Is Cencora a profitable company?
Yes, Cencora is a profitable company. In fiscal year 2025, the company reported revenue of $321.3 billion (up 9.3%), net income of $1.6 billion, and adjusted diluted EPS of $16.00 (up 16.3%). The company has a market capitalization of approximately $70–72 billion as of early 2026.
Article last updated:March 2026March 3, 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including SEC filings, official company press releases, and reputable news outlets. Net worth figures are estimates based on disclosed stock holdings and may vary by source. This content is provided for informational purposes only and does not constitute financial or investment advice.